Which criteria should we use to evaluate the efficacy of immune-checkpoint inhibitors?

Yuki Kataoka^{1

2}, Katsuya Hirano²

Affiliations

¹ Hospital Care Research Unit Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.
² Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.

Editorial

Yuki Kataoka et al. Ann Transl Med. 2018 Jun.

. 2018 Jun;6(11):222.

doi: 10.21037/atm.2018.04.17.

Yuki Kataoka^{1

2}, Katsuya Hirano²

¹ Hospital Care Research Unit Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.
² Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.
Hodi FS, Ballinger M, Lyons B, Soria JC, Nishino M, Tabernero J, Powles T, Smith D, Hoos A, McKenna C, Beyer U, Rhee I, Fine G, Winslow N, Chen DS, Wolchok JD. Hodi FS, et al. J Clin Oncol. 2018 Mar 20;36(9):850-858. doi: 10.1200/JCO.2017.75.1644. Epub 2018 Jan 17. J Clin Oncol. 2018. PMID: 29341833

1. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348:56-61. 10.1126/science.aaa8172 - DOI - PubMed
1. Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clin Cancer Res 2009;15:7412-20. 10.1158/1078-0432.CCR-09-1624 - DOI - PubMed
1. Robert C, Ribas A, Hamid O, et al. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. J Clin Oncol 2018;36:1668-74. - PubMed
1. Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol 2017;35:3924-33. 10.1200/JCO.2017.74.3062 - DOI - PMC - PubMed
1. Rizvi H, Sanchez-Vega F, La K, et al. Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. J Clin Oncol 2018;36:633-41. 10.1200/JCO.2017.75.3384 - DOI - PMC - PubMed